Thioredoxin in cancer--role of histone deacetylase inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Elevated thioredoxin (Trx) levels in human cancers can confer resistance to therapy by neutralizing reactive oxygen species (ROS).
• Many cancers exhibit low levels of thioredoxin-binding protein (TBP-2), an inhibitor of Trx activity.

Purpose of the Study:

• To investigate the role of histone deacetylase inhibitors (HDACi) in modulating Trx and TBP-2 levels in cancer.
• To determine if altering Trx and TBP-2 levels impacts cancer cell sensitivity to HDACi.

Main Methods:

• The study examined the effects of HDAC inhibitors on TBP-2 and Trx expression in various cancer cell types.
• Analysis focused on the correlation between changes in TBP-2 and Trx levels and the anti-cancer activity of HDAC inhibitors.

Main Results:

• Histone deacetylase inhibitors (HDACi) were found to up-regulate TBP-2 expression in transformed cells.
• This up-regulation of TBP-2 was associated with a significant decrease in Trx levels.
• The observed decrease in Trx levels correlated with enhanced sensitivity of hematologic and solid tumors to HDACi therapy.

Conclusions:

• HDAC inhibitors modulate the Trx/TBP-2 balance, potentially overcoming therapy resistance.
• Targeting the Trx system via TBP-2 up-regulation represents a promising strategy for enhancing anti-cancer therapies.